An investigation for investors in Coherus Biosciences Inc (NASDAQ:CHRS) shares over potential securities laws violations was announced and Coherus Biosciences Inc (NASDAQ:CHRS stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 06/23/2017 --An investigation on behalf of investors of Coherus Biosciences Inc (NASDAQ:CHRS) shares over potential securities laws violations was announced.

Investors who purchased shares of Coherus Biosciences Inc (NASDAQ:CHRS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether a series of statements regarding Coherus Biosciences' business, its prospects and its operations were materially false and misleading at the time they were made.

Redwood City, CA based Coherus BioSciences, Inc. is a late-stage clinical biologics platform company that is engaged in the business of developing and commercializing biosimilar products. On June 12, 2017, Coherus Biosciences Inc announced that the U.S. Food and Drug Administration ("FDA") has issued a complete response letter ("CRL") for its biologics license application ("BLA") for CHS-1701, a pegfilgrastim (Neulasta®) biosimilar candidate, under the 351(k) pathway. Shares of Coherus Biosciences Inc (NASDAQ:CHRS) declined on June 12, 2017 to $14.05 per share.

On June 22, 2017, NASDAQ:CHRS shares closed at $15.80 per share.

Those who purchased shares of Coherus Biosciences Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com